# A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

> **NCT04012931** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 26 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Rilpivirine
- **DRUG:** ARV Background Regimen

## Key facts

- **NCT ID:** NCT04012931
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-18
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-02-23
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04012931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04012931, "A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04012931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*